End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study

被引:4
|
作者
Molaoa, Thabang T. [1 ]
Bisiwe, Feziwe B. [1 ]
Ndlovu, Kwazi C. Z. [2 ,3 ]
机构
[1] Univ Free State, Div Nephrol, Dept Internal Med, Bloemfontein, South Africa
[2] Univ Cape Town, Div Nephrol & Hypertens, Cape Town, South Africa
[3] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa
关键词
Incidence rate; End-stage kidney disease; Kidney replacement therapy; Dialysis access; South Africa; SUB-SAHARAN-AFRICA; RENAL-DISEASE; PERITONEAL-DIALYSIS; HEALTH-CARE; TRANSPLANTATION; PREVENTION; PREVALENCE; OUTCOMES; OLDER; HIV;
D O I
10.1186/s12882-021-02387-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background End-stage kidney disease (ESKD) and the required kidney replacement therapy (KRT) are significant public health challenges for low-and-middle-income countries. The South African government adopted a KRT rationing policy to balance the growing need for KRT and scarce resources. We aimed to describe the epidemiology and KRT access in patients with ESKD referred to the main public sector hospital in the Free State Province, South Africa. Methods A retrospective study of adult patients with ESKD admitted to Universitas Academic Hospital for KRT, was conducted between 1 January 2016 and 31 December 2018. A review of the KRT committee decisions to offer or deny KRT based on the KRT rationing policy of the Free State was undertaken. Demographic information, KRT committee outcomes, laboratory test results, and clinical details were collected from assessment tools, KRT committee meeting diaries, and electronic hospital records. Results Of 363 patients with ESKD referred for KRT access, 96 with incomplete records were excluded and 267 were included in the analysis. Median patient age was 40 (interquartile range, 33-49) years, and male patients accounted for 56.2 % (150/267, p = 0.004) of the cohort. The average annual ESKD incidence was 49.9 (95 % confidence interval [CI], 35.8-64.0) per-million-population. The most prevalent comorbidities were hypertension (42.3 %; 113/267), human immunodeficiency virus (HIV) (28.5 %; 76/267), and diabetes mellitus (19.1 %; 51/267). The KRT access rate was 30.7 % (82/267), with annual KRT incidence rates of 8.05 (95 % CI, 4.98-11.1), 11.5 (95 % CI, 7.83-15.1), and 14.1 (95 % CI, 10.3-18.0) per-million-population in 2016, 2017, and 2018, respectively. Advanced organ dysfunction was the commonest reason recorded for KRT access denial (58.9 %; 109/185). Age (odds ratio [OR], 1.04; 95 % CI, 1.00-1.07; p = 0.024) and diabetes (OR, 5.04; CI, 1.69-15.03; p = 0.004) were independent predictors for exclusion from KRT, while hypertension (OR, 1.80; 1.06-3.04; p = 0.029) independently predicted advanced organ dysfunction resulting in KRT exclusion. Conclusions Non-communicable and communicable diseases, including hypertension, diabetes, and HIV, contributed to ESKD, highlighting the need for improved early prevention strategies to address a growing incidence rate. Two-thirds of ESKD patients were unable to access KRT, with age, diabetes mellitus, and advanced organ dysfunction being significant factors adversely affecting KRT access.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] End-stage kidney disease in Fiji
    Krishnan, Amrish
    Chandra, Yogeshni
    Malani, Joji
    Jesudason, Shilpanjali
    Sen, Shaundeep
    Ritchie, Angus G.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (04) : 461 - 466
  • [22] Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study
    Andrew S Allegretti
    David JR Steele
    Jo Ann David-Kasdan
    Ednan Bajwa
    John L Niles
    Ishir Bhan
    Critical Care, 17
  • [23] Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study
    Allegretti, Andrew S.
    Steele, David J. R.
    David-Kasdan, Jo Ann
    Bajwa, Ednan
    Niles, John L.
    Bhan, Ishir
    CRITICAL CARE, 2013, 17 (03):
  • [24] Continuous renal replacement therapy for end-stage renal disease - The wearable artificial kidney (WAK)
    Gura, V
    Beizai, M
    Ezon, C
    Polaschegg, HD
    CARDIOVASCULAR DISORDERS IN HEMODIALYSIS, 2005, 149 : 325 - 333
  • [25] Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community
    Van Biesen, Wim
    Vanholder, Raymond
    Vanderhaegen, Bert
    Lameire, Norbert
    Wanner, Christoph
    Wiecek, Andrzej
    Sever, Mehmet S.
    Feehally, Johan
    Kazancioglu, Remuyza
    Rondeau, Eric
    Levin, Adeera
    Harris, David
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2016, 6 (02) : 35 - 41
  • [26] New Targets for End-Stage Chronic Kidney Disease Therapy
    Prakoura, Niki
    Kavvadas, Panos
    Chatziantoniou, Christos
    JOURNAL OF CRITICAL CARE MEDICINE, 2015, 1 (03): : 92 - 95
  • [27] Cerebrovascular disease in end-stage kidney disease
    Tsuruya K.
    Fujisaki K.
    Renal Replacement Therapy, 2 (1)
  • [28] Morbidity burden of end-stage kidney disease in Australia: Hospital separation rates among people receiving kidney replacement therapy
    Mcdonald, Stephen P.
    Tong, Bin
    NEPHROLOGY, 2011, 16 (08) : 758 - 766
  • [29] A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease
    Nyokabi, Patricia
    Youngkong, Sitaporn
    Bagepally, Bhavani Shankara
    Okech, Tabitha
    Chaikledkaew, Usa
    McKay, Gareth J.
    Attia, John
    Thakkinstian, Ammarin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [30] End of life care in end-stage kidney disease
    Prabhu, Ravindra Attur
    Salins, Naveen
    Bharathi
    Abrahams, Georgi
    INDIAN JOURNAL OF PALLIATIVE CARE, 2021, 27 (05) : 37 - 42